These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1798957)

  • 1. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
    Schneider J
    Thromb Res; 1991 Dec; 64(6):677-89. PubMed ID: 1798957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
    Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
    Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
    Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
    Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G
    Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
    J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
    Sabatine MS; Tu TM; Jang IK
    J Thromb Thrombolysis; 2000 Oct; 10(2):189-96. PubMed ID: 11005941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
    Berry CN; Girard D; Girardot C; Lochot S; Lunven C; Visconte C
    Semin Thromb Hemost; 1996; 22(3):233-41. PubMed ID: 8836007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model.
    Kornowski R; Chernine A; Hasdai D; Ovadia Z; Battler A
    Eur Heart J; 1995 Feb; 16(2):177-83. PubMed ID: 7744088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ; Connolly TM; York SJ; Bush LR
    Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of saruplase with acetylsalicylic acid, heparin, glyceryl trinitrate, tranexamic acid and aprotinin in a rabbit pulmonary thrombosis model.
    Schneider J
    Arzneimittelforschung; 1990 Oct; 40(10):1180-4. PubMed ID: 1705427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.
    Valji K; Arun K; Bookstein JJ
    J Vasc Interv Radiol; 1995; 6(1):91-5. PubMed ID: 7703589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
    Kornowski R; Glikson M; Hasdai D; Chernine A; Ohad D; Battler A
    Eur Heart J; 1994 Apr; 15(4):541-6. PubMed ID: 8070483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
    Jang IK; Gold HK; Ziskind AA; Leinbach RC; Fallon JT; Collen D
    Circulation; 1990 Jan; 81(1):219-25. PubMed ID: 2297828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
    Kawasaki T; Sato K; Hirayama F; Koshio H; Taniuchi Y; Matsumoto Y
    Thromb Haemost; 1998 Apr; 79(4):859-64. PubMed ID: 9569205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.